华润医药(03320.HK) 公布，集团参股公司永泰生物制药(06978.HK) 的核心产品候选药物EAL近期取得重要进展。据永泰生物与国家药监局药品审评中心的沟通，药品审评中心已同意永泰生物可为其核心产品候选药物EAL提交附条件批准申请。
据介绍，EAL属广谱性的细胞免疫治疗产品，为最初取自患者自体外周血中的T细胞经使用专利方法活化、扩增培育而成的制剂。产品以CD8+杀伤性T细胞为主要活性成分。
华润医药表示，集团将继续与永泰生物合作，共同开发中国细胞免疫治疗市场，推进行业标准建立及双方业务协同发展。(js/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-28 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.